SinoMab BioScience (FRA:4VF) 6-Month Share Buyback Ratio: -15.12% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4VF SinoMab BioScience Ltd FRA:4VF
19 GF Score
Price €0.12
! 2 Warning Signs
View Full Analysis

What is SinoMab BioScience 6-Month Share Buyback Ratio?

SinoMab BioScience FRA:4VF 19 6-Month Share Buyback Ratio is -15.12 as of Dec. 2025. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. SinoMab BioScience's current 6-Month Share Buyback Ratio was -15.12%.

SinoMab BioScience  (FRA:4VF) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

SinoMab BioScience 6-Month Share Buyback Ratio Related Terms

FRA:4VF vs VRTX, REGN, MRNA: 6-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, SinoMab BioScience's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SinoMab BioScience 6-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's 6-Month Share Buyback Ratio falls into.


FRA:4VF
19GF Score
SinoMab BioScience Ltd FRA:4VF
6-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SinoMab BioScience 6-Month Share Buyback Ratio Calculation

SinoMab BioScience's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2025 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Jun. 2025 )
=(1204.566 - 1386.638) / 1204.566
=-15.12%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of -15.12 mean?
SinoMab BioScience (FRA:4VF) has a 6-Month Share Buyback Ratio of -15.12 as of Dec. 2025. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for SinoMab BioScience and its competitors.
Is SinoMab BioScience's 6-Month Share Buyback Ratio too high?
SinoMab BioScience's current 6-Month Share Buyback Ratio is -15.12. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's 6-Month Share Buyback Ratio compare to VRTX and REGN?
SinoMab BioScience's 6-Month Share Buyback Ratio of -15.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Biotechnology company?
A good 6-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for SinoMab BioScience and its competitors. SinoMab BioScience's current 6-Month Share Buyback Ratio is -15.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current 6-Month Share Buyback Ratio of -15.12. The current 6-Month Share Buyback Ratio is -15.12. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current 6-Month Share Buyback Ratio is -15.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SinoMab BioScience Business Description

Other Exchanges 03681:Hong Kong
Address No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score

Get the complete analysis for FRA:4VF

6-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price